Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Journal of Clinical Oncology, Vol 16, 3832-3842, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group


PURPOSE: To compare combination chemotherapy (CCT) versus melphalan plus prednisone (MP) as treatment for multiple myeloma. PATIENTS AND METHODS: In a collaborative worldwide overview of randomized trials of CCT versus MP, individual patient data on 4,930 patients from 20 trials were analyzed, with the addition of published data on a further 1,703 patients from seven trials. The main outcome measure was mortality, with response and recurrence rates being subsidiary end points. RESULTS: Taking all of the trials together, response rates were significantly higher with CCT than with MP (60.0% v 53.2%; P < .00001, two-tailed). There was no evidence of any difference in mortality between CCT and MP, with a nonsignificant 1.5% reduction in death rate in favor of CCT (P = .6, two-tailed). There is heterogeneity of design between the trials, but subgroup analyses by type of CCT or by dose- intensities of CCT, of melphalan, or of prednisone did not identify any particular forms of therapy that were either clearly beneficial or clearly adverse. Similarly, analysis of the presentation features of the patients did not find any categories in which CCT differed significantly from MP in its effects on mortality; in particular, there was no evidence that poor-risk patients benefited more from CCT. CONCLUSION: This overview found no difference, either overall or within any subgroup, in mortality between CCT and MP. In terms of survival, these therapeutic options, as tested in the trials considered, are approximately equivalent.


This article has been cited by other articles:


Home page
 JCOHome page
J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
J. Clin. Oncol., December 10, 2008; 26(35): 5775 - 5782.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Paiva, M.-B. Vidriales, J. Cervero, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. G. de Coca, et al.
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood, November 15, 2008; 112(10): 4017 - 4023.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, N. Giuliani, L. Mazzera, G. Lombardi, M. Ricca, A. Corradi, A. M. Cantoni, L. Salvatore, R. Riccioni, A. Costanzo, et al.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways
Blood, September 15, 2008; 112(6): 2450 - 2462.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al.
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N. Engl. J. Med., August 28, 2008; 359(9): 906 - 917.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M.-V. Mateos, J. M. Hernandez, M. T. Hernandez, N. C. Gutierrez, L. Palomera, M. Fuertes, P. Garcia-Sanchez, J. J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
Haematologica, April 1, 2008; 93(4): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, S. R. Zeldenrust, D. Dingli, S. J. Russell, J. A. Lust, et al.
Improved survival in multiple myeloma and the impact of novel therapies
Blood, March 1, 2008; 111(5): 2516 - 2520.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. V. Rajkumar and S. R. Hayman
Controversies Surrounding the Initial Treatment of Multiple Myeloma
ASCO Educational Book, January 1, 2008; 2008(1): 369 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omede, M. T. Ambrosini, et al.
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network
J. Clin. Oncol., October 1, 2007; 25(28): 4459 - 4465.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K Zervas, D Mihou, E Katodritou, A Pouli, C. Mitsouli, A Anagnostopoulos, S Delibasi, M. Kyrtsonis, N Anagnostopoulos, E Terpos, et al.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
Ann. Onc., August 1, 2007; 18(8): 1369 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Di Raimondo, E. Volpe, S. Ronconi, D. Cangini, et al.
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
J. Clin. Oncol., June 10, 2007; 25(17): 2434 - 2441.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al.
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Y. Kristinsson, O. Landgren, P. W. Dickman, A. R. Derolf, and M. Bjorkholm
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
J. Clin. Oncol., May 20, 2007; 25(15): 1993 - 1999.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
L. Cook and D. H C Macdonald
Management of paraproteinaemia
Postgrad. Med. J., April 1, 2007; 83(978): 217 - 223.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Palumbo, M. T. Ambrosini, G. Benevolo, P. Pregno, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Musto, et al.
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Blood, April 1, 2007; 109(7): 2767 - 2772.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Muto, M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, et al.
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Mol. Cancer Ther., March 1, 2007; 6(3): 987 - 994.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327.
[Full Text] [PDF]

Home page
 BloodHome page
P. G. Richardson, E. Blood, C. S. Mitsiades, S. Jagannath, S. R. Zeldenrust, M. Alsina, R. L. Schlossman, S. V. Rajkumar, K. R. Desikan, T. Hideshima, et al.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Blood, November 15, 2006; 108(10): 3458 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Offidani, L. Corvatta, M.-N. Piersantelli, G. Visani, F. Alesiani, M. Brunori, P. Galieni, M. Catarini, M. Burattini, R. Centurioni, et al.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Blood, October 1, 2006; 108(7): 2159 - 2164.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood, October 1, 2006; 108(7): 2165 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
M. A. Hussein, R. Baz, G. Srkalovic, N. Agrawal, R. Suppiah, E. Hsi, S. Andresen, M. A. Karam, J. Reed, B. Faiman, et al.
Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma
Mayo Clin. Proc., July 1, 2006; 81(7): 889 - 895.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood, May 15, 2006; 107(10): 4053 - 4062.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Haubitz and D. Peest
Myeloma - new approaches to combined nephrological-haematological management
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 582 - 590.
[Full Text] [PDF]

Home page
 JCOHome page
J. R. Berenson, H. H. Yang, K. Sadler, S. G. Jarutirasarn, R. A. Vescio, R. Mapes, M. Purner, S.-p. Lee, J. Wilson, B. Morrison, et al.
Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol., February 20, 2006; 24(6): 937 - 944.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Facon, J.-Y. Mary, B. Pegourie, M. Attal, M. Renaud, A. Sadoun, L. Voillat, V. Dorvaux, C. Hulin, G. Lepeu, et al.
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Blood, February 15, 2006; 107(4): 1292 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
J. Clin. Oncol., January 20, 2006; 24(3): 334 - 336.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 338 - 347.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. V. Rajkumar, S. R. Hayman, M. Q. Lacy, A. Dispenzieri, S. M. Geyer, B. Kabat, S. R. Zeldenrust, S. Kumar, P. R. Greipp, R. Fonseca, et al.
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Blood, December 15, 2005; 106(13): 4050 - 4053.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Blade, L. Rosinol, A. Sureda, J. M. Ribera, J. Diaz-Mediavilla, J. Garcia-Larana, M. V. Mateos, L. Palomera, J. Fernandez-Calvo, J. M. Marti, et al.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Blood, December 1, 2005; 106(12): 3755 - 3759.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Oshima, M. Abe, J. Asano, T. Hara, K. Kitazoe, E. Sekimoto, Y. Tanaka, H. Shibata, T. Hashimoto, S. Ozaki, et al.
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Blood, November 1, 2005; 106(9): 3160 - 3165.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
G. Saunders
Overview of drug therapy for multiple myeloma
Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H. Yasui, T. Hideshima, N. Raje, A. M. Roccaro, N. Shiraishi, S. Kumar, M. Hamasaki, K. Ishitsuka, Y.-T. Tai, K. Podar, et al.
FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
Cancer Res., August 15, 2005; 65(16): 7478 - 7484.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
Blood, July 15, 2005; 106(2): 706 - 712.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
Blood, June 1, 2005; 105(11): 4470 - 4476.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Palumbo, S. Bringhen, M. T. Petrucci, P. Musto, F. Rossini, M. Nunzi, V. M. Lauta, C. Bergonzi, A. Barbui, T. Caravita, et al.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
Blood, November 15, 2004; 104(10): 3052 - 3057.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873.
[Full Text] [PDF]

Home page
 BloodHome page
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al.
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
Blood, October 15, 2004; 104(8): 2484 - 2491.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. F. Bross, R. Kane, A. T. Farrell, S. Abraham, K. Benson, M. E. Brower, S. Bradley, J. V. Gobburu, A. Goheer, S.-L. Lee, et al.
Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma
Clin. Cancer Res., June 15, 2004; 10(12): 3954 - 3964.
[Full Text] [PDF]

Home page
 BloodHome page
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley
Treatment of multiple myeloma
Blood, January 1, 2004; 103(1): 20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Attal, J.-L. Harousseau, T. Facon, F. Guilhot, C. Doyen, J.-G. Fuzibet, M. Monconduit, C. Hulin, D. Caillot, R. Bouabdallah, et al.
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., December 25, 2003; 349(26): 2495 - 2502.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al.
Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma
Cancer Res., December 1, 2003; 63(23): 8428 - 8436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Blade, D. H. Vesole, and M. Gertz
Transplantation for multiple myeloma: who, when, how often?
Blood, November 15, 2003; 102(10): 3469 - 3477.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. Kaufmann, J. Ackermann, H. Greinix, T. Nosslinger, H. Gisslinger, A. Keck, H. Ludwig, N. Worel, P. Kalhs, C. Zielinski, et al.
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
Ann. Onc., November 1, 2003; 14(11): 1667 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Zhou, Y. Zhang, C. Martinez, N. Kalakonda, S. D. Nimer, and R. L. Comenzo
Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination
Blood, July 15, 2003; 102(2): 477 - 479.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. M. Lokhorst, C. M. Segeren, L. F. Verdonck, B. van der Holt, R. Raymakers, M. H.J. van Oers, R. M.Y. Barge, H. C. Schouten, P. H.M. Westveer, M. M.C. Steijaert, et al.
Partially T-Cell-Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM
J. Clin. Oncol., May 1, 2003; 21(9): 1728 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Segeren, P. Sonneveld, B. van der Holt, E. Vellenga, A. J. Croockewit, G. E. G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H. J. van Oers, P. W. Wijermans, et al.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
Blood, March 15, 2003; 101(6): 2144 - 2151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Weber, K. Rankin, M. Gavino, K. Delasalle, and R. Alexanian
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
J. Clin. Oncol., January 1, 2003; 21(1): 16 - 19.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology, January 1, 2003; 2003(1): 248 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. S. Dalton
Targeting the Mitochondria: An Exciting New Approach to Myeloma Therapy: Commentary re: N. J. Bahlis et al., Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Clin. Cancer Res., December 1, 2002; 8(12): 3643 - 3645.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Dingli, M. Timm, S. J. Russell, T. E. Witzig, and S. V. Rajkumar
Promising Preclinical Activity of 2-Methoxyestradiol in Multiple Myeloma
Clin. Cancer Res., December 1, 2002; 8(12): 3948 - 3954.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Hashimoto, S. Ozaki, S. Wakatsuki, M. Kosaka, S. Kido, D. Inoue, et al.
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma
Blood, August 28, 2002; 100(6): 2195 - 2202.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A.-T. Brenne, T. Baade Ro, A. Waage, A. Sundan, M. Borset, and H. Hjorth-Hansen
Interleukin-21 is a growth and survival factor for human myeloma cells
Blood, May 15, 2002; 99(10): 3756 - 3762.
[Abstract] [Full Text] [PDF]